F
Firefly Bio
Unlocking new classes of payloads to maximize the potential of ADCs
About Firefly Bio
Firefly Biologics is a venture-backed company based in the Bay Area, currently operating in stealth mode. The company focuses on developing innovative bioconjugate solutions, which are advanced techniques that combine biological molecules with other compounds to enhance their effectiveness in medical treatments. Firefly Biologics aims to revolutionize the field of medicine by realizing the full potential of bioconjugates, making treatments more effective and targeted.
The company primarily serves the biotechnology and pharmaceutical sectors, targeting clients who are looking for cutting-edge solutions to improve their medical products. Operating in the highly competitive and rapidly evolving biotech market, Firefly Biologics leverages its advanced research and development capabilities to stay ahead.
Firefly Biologics' business model revolves around research and development, intellectual property licensing, and strategic partnerships. The company generates revenue through licensing its bioconjugate technologies to pharmaceutical companies and forming partnerships for co-development of new medical treatments. By focusing on innovation and collaboration, Firefly Biologics aims to create significant value for its stakeholders.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2022
- Headquarters
- South San Francisco, United States
- Employees
- 25
- Open positions
- None listed
- Dealroom signal
- 62.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Antibodies, Spinout, Verified Unicorns and $1B Exits, Biotech and Pharma, Antibody-Drug Conjugate, Woman Founder, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jun 2026 | $1B | $1B | Johnson & Johnson | ↗ |
| SERIES AOther financing | Feb 2024 | $94M | $376M | Eli Lilly · MPM BioImpact · Versant Ventures · Decheng Capital | ↗ |
Growth signals
Latest recorded traffic for Firefly Bio is 1.5K monthly website visits, up 54.6% over the last three months. Firefly Bio's team declined 3.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Eli Lilly
MPM BioImpact
Versant Ventures
Decheng Capital
Other known investors2 additional known investors
Johnson & Johnson
Stanford University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Firefly Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Firefly Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.